Scott Heflick
Family Medicine · Yakima, WANPI 1518975762
Payments from drug & device makers
Across 323 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$953
- AstraZeneca$658
- Pfizer$651
- Boehringer Ingelheim$462
- Novo Nordisk$344
- GSK$303
- plus $2K from 36 others
What the payments were for
- Food & beverage$5,325100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,348 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 68 | $72,526 |
| OzempicSemaglutide | 62 | $55,933 |
| EliquisApixaban | 46 | $50,161 |
| FarxigaDapagliflozin Propanediol | 39 | $27,492 |
| JardianceEmpagliflozin | 19 | $26,099 |
| Repatha SyringeEvolocumab | 22 | $17,735 |
| RybelsusSemaglutide | 14 | $16,752 |
| Spiriva HandihalerTiotropium Bromide | 16 | $15,985 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $12,682 |
| JanuviaSitagliptin Phosphate | 19 | $11,176 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $10,269 |
| VascepaIcosapent Ethyl | 22 | $7,792 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $7,571 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,160 |
| Lisinopril | 471 | $4,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $344 | $72,68576 claims |
| Lilly USA, LLCTrulicity | $15 | $72,52668 claims |
| PfizerEliquis | $651 | $50,16146 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $462 | $38,78137 claims |
| AstraZenecaFarxiga, Symbicort | $658 | $34,65259 claims |
| MerckJanuvia | $14 | $11,17619 claims |
| GSKBreo Ellipta | $303 | $10,26915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Yakima
- Theodore VyeYakima$17K
- Portia JonesYakima$16K
- Vani BremjitYakima$14K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.